Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

Alan Meds vs FORM by GBY

Two GLP-1 deals, scored on the same six factors. Alan Meds lands a Value Score of 90, FORM by GBY a 61. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

Alan Meds

#7 · Grade A · Best Value

Est. first month

$99/mo

Save ~93% vs brand-name
Get this deal Full Alan Meds review →
VS

FORM by GBY

#344 · Grade C · Watch List

Est. first month

$299/mo

Save ~78% vs brand-name
Get this deal Full FORM by GBY review →

The verdict

Better value: Alan Meds

Alan Meds takes it on Value Score, 90 to 61 an est. $99/mo first month, with no teaser step-up baked in. FORM by GBY isn't out of it: Shoppers who want the widest single-account menu and are willing to complete intake to learn what the branded and adjacent-care lines actually cost.

Our #1 overall:Neither of these is our top pick — that's CoreAge Rx (Value Score 93).See why →

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealAlan MedsFORM by GBY
Value Score90 (A)61 (C)
Est. first month$99/mo$299/mo
Save vs brand-name~93%~78%
Semaglutide$99/mo$299/mo (compounded, no dose tiers published)
Tirzepatide$145/moNot disclosed (Zepbound membership offered, drug cost not published)
Both moleculesYesYes
PricingFlat — no step-upWatch
CoverageAll 50 states48 states + DC (excludes Alaska, Mississippi)

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

95
Lowest Real Price
48
Alan Meds: 95. FORM by GBY: 48.
85
No Teaser-Rate Bait
32
Alan Meds: 85. FORM by GBY: 32.
98
Nationwide Availability
84
Alan Meds: 98. FORM by GBY: 84.
94
Both Molecules
70
Alan Meds: 94. FORM by GBY: 70.
82
Easy Cancellation
70
Alan Meds: 82. FORM by GBY: 70.
72
Reputation
62
Alan Meds: 72. FORM by GBY: 62.

Alan Meds

Double-digit semaglutide ($99) and a $145 tirzepatide, both nationwide, with an oral route for the needle-shy.

Why it's a deal

  • $99 flat semaglutide and a low $145 tirzepatide
  • Available in all 50 states
  • Offers an oral/sublingual route

The fine print

  • Not LegitScript-certified — do your own pharmacy diligence
  • Newer operator with a thin public track record

FORM by GBY

The broadest menu on the board — compounded and branded GLP-1s, NAD+/sermorelin, and hair loss on one account — but the advertised Wegovy "$95/mo" is a membership fee only, not the drug cost, and almost nothing else is priced.

Why it's a deal

  • Widest published menu on this board: compounded GLP-1 (injectable and oral), branded Wegovy/Zepbound, NAD+/sermorelin/GHK-Cu/glutathione, and hair loss on one account
  • Compounded semaglutide has a real, published sticker price ($299/mo)
  • LegitScript-approved and HIPAA-compliant badges displayed

The fine print

  • ⚠ The advertised Wegovy "$95/mo" is a MEMBERSHIP FEE ONLY — the actual medication cost is billed separately and is not disclosed anywhere on the page. Do not read $95 as the all-in Wegovy price
  • No published price for tirzepatide, Zepbound, NAD+, sermorelin, or the hair-loss line — compounded semaglutide is the only dosed figure on the whole site
  • No named medical director or doctors; the pharmacy is identified only as generic "US licensed pharmacies," not by name
  • Does not serve Alaska or Mississippi
Get the Alan Meds deal Get the FORM by GBY deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores Alan Meds is ranked on the Alan Meds alternatives board, and the same list for the other side is on alternatives to FORM by GBY.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.